The best
in our field


A national network of partners

  • Neurocentre Magendie, INSERM, University of Bordeaux (France)

Aelis Farma first established its research and development on an exclusive collaboration with the Neurocentre Magendie in Bordeaux, one of the most respected and highly innovative Neuroscience Research centers in Europe with extensive experience in the CB1 receptor.




An international network of partners

Aelis Farma also collaborate with a panel of other prestigious research organization and laboratories which provide the company with an outstanding expertise in the field of signaling specific drugs for the CB1 receptor and other similar GPCRs:


  • Universitat Pompeu Fabra (Barcelona, Spain)
    – Pr. Rafael Maldonado
  • Columbia University (New York, USA)
    – Pr. Margaret Haney
  • Yale University (New Haven, USA)
    –Dr Patricia Reggio
  • University of Auckland (New Zeland)
    – Pr. Michelle Glass
  • National Institute on Drug Abuse (NIDA, NIH) intramural program (Bethesda, USA)
    – Pr. Yavin Shaham
  • NIDA extramural program (Bethesda, USA)
    – In collaboration with Pr. Haney (Columbia University), Aelis Farma has been awarded a strategic alliance grant (3.3 M USD) for the first clinical studies of AEF0117 for the treatment of cannabis abuse




Financial partners

In collaboration with Columbia University, Aelis Farma has been granted a 3.3 MUSD financing from NIDA (National Institute on Drug Abuse) in order to finance the first clinical studies for its lead compound AEF0117 in the treatment of cannabis abuse. To comply with specific NIH requirements, Aelis Farma has set up a FCOI (Financial Conflicts of Interest) policy:fcoi-policy-aelis-farma



Inserm Transfert Initiative
BPI France Participations
Aquitaine Création Investissement
Aquitaine Co-Invest
Aelis Innovation




This internet site is co-financed by the European Union and the New Aquitaine Region.
L’Europe s’engage en Nouvelle Aquitaine avec les Fonds Européens de Développement Régional.

The best
in our field